The antitumor effect of a novel angiogenesis inhibitor (an octahydronaphthalene derivative) targeting both VEGF receptor and NF-κB pathway

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages 310-321

  Watari, Kosuke ^a   Nakamura, Mamiyo ^a   Fukunaga, Yuichi ^a   Furuno, Ayana ^a   Shibata, Tomohiro ^a   Kawahara, Akihiko ^b   Hosoi, Fumihito ^a   Kuwano, Takashi ^c   Kuwano, Michihiko ^a   Ono, Mayumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

anti angiogenesis; IL 1 ; NF B; octahydronaphthalene compound; VEGFR

Indexed keywords

AMF 26; ANTINEOPLASTIC AGENT; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (PYRIDIN 3 YLMETHYL) 5 (7 HYDROXY 2,6,8 TRIMETHYL 1,2,4A,5,6,7,8,8A OCTAHYDRONAPHTHALEN 1 YL) 2 METHYLPENTA 2,4 DIENAMIDE; PROTEIN KINASE B; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; CORNEA TUMOR; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MELANOMA; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; I-KAPPA B PROTEINS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NAPHTHOLS; NEOVASCULARIZATION, PHYSIOLOGIC; NF-KAPPA B; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856711611     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26356     Document Type: Article

References (43)

1. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F,. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-8.
2. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H,. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006; 24: 217-27.
3. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D,. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006; 13: 1845-57.
4. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C,. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009; 115: 61-7.
5. Khan G, Golshayan A, Elson P, Wood L, Garcia J, Bukowski R, Rini B,. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol 2010; 21: 1618-22.
6. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, Harmon C, Ruiz-Garcia A, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009; 10: 794-800.
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
8. Hanahan D, Folkman J,. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
9. Costa C, Incio J, Soares R,. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 2007; 10: 149-66.
10. Lin WW, Karin M,. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-83.
11. Ono M,. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008; 99: 1501-6.
12. Shono T, Ono M, Izumi H, Jimi SI, Matsushima K, Okamoto T, Kohno K, Kuwano M,. Involvement of the transcription factor NF-κB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 1996; 16: 4231-9.
13. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K, Kuwano M,. Induction of vascular endothelial growth factor by tumor necrosis factor α in human glioma cells. Possible roles of SP-1. J Biol Chem 1996; 271: 28220-8.
14. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, Kuwano M,. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor α-dependent angiogenesis. Mol Cell Biol 1997; 17: 4015-23.
15. Kuwano T, Nakao S, Yamamoto H, Tsuneyoshi M, Yamamoto T, Kuwano M, Ono M,. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J 2004; 18: 300-10.
16. Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda S, Kimura YN, Hamano S, Sonoda KH, Saijo Y, Nukiwa T, Strieter RM, Ishibashi T, Kuwano M, et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 β-induced neovascularization and tumor growth. J Clin Invest 2005; 115: 2979-91.
17. Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, Nishioka Y, Sone S, Kuwano M,. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFα and IL-1α. Int J Cancer 2000; 85: 182-8.
18. Karin M,. Nuclear factor-κB in cancer development and progression. Nature 2006; 441: 431-6.
19. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY,. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-κB activation in endothelial cells. J Biol Chem 2001; 276: 7614-20.
20. Grosjean J, Kiriakidis S, Reilly K, Feldmann M, Paleolog E,. Vascular endothelial growth factor signalling in endothelial cell survival: a role for NFκB. Biochem Biophys Res Commun 2006; 340: 984-94.
21. Amin MA, Haas CS, Zhu K, Mansfield PJ, Kim MJ, Lackowski NP, Koch AE,. Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via src, PI3 kinase, and NFκB. Blood 2006; 107: 2252-61.
22. Roebuck KA, Finnegan A,. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol 1999; 66: 876-88.
23. Fukushi J, Ono M, Morikawa W, Iwamoto Y, Kuwano M,. The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13. J Immunol 2000; 165: 2818-23.
24. Nakao S, Kuwano T, Ishibashi T, Kuwano M, Ono M,. Synergistic effect of TNF-α in soluble VCAM-1-induced angiogenesis through α 4 integrins. J Immunol 2003; 170: 5704-11.
25. Francavilla C, Maddaluno L, Cavallaro U,. The functional role of cell adhesion molecules in tumor angiogenesis. Semin Cancer Biol 2009; 19: 298-309.
26. Itokawa T, Nokihara H, Nishioka Y, Sone S, Iwamoto Y, Yamada Y, Cherrington J, McMahon G, Shibuya M, Kuwano M, Ono M,. Antiangiogenic effect by SU5416 is partly attributable to inhibition of flt-1 receptor signaling. Mol Cancer Ther 2002; 1: 295-302.
27. Takahashi T, Shibuya M,. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 1997; 14: 2079-89.
28. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, Ono M,. ZD1839 (iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62: 2554-60.
29. Furuno A, Watari K, Nakamura M, Fukunaga Y, Jung JH, Ono M,. A natural anti-inflammatory enone fatty acid inhibits angiogenesis by attenuating nuclear factor-κB signaling in vascular endothelial cells. Int J Oncol 2011; 38: 493-501.
30. Watari K, Nakao S, Fotovati A, Basaki Y, Hosoi F, Bereczky B, Higuchi R, Miyamoto T, Kuwano M, Ono M,. Role of macrophages in inflammatory lymphangiogenesis: enhanced production of vascular endothelial growth factor C and D through NF-κB activation. Biochem Biophys Res Commun 2008; 377: 826-31.
31. Ueda S, Basaki Y, Yoshie M, Ogawa K, Sakisaka S, Kuwano M, Ono M,. PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by Gefitinib. Cancer Res 2006; 66: 5346-53.
32. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D,. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270: 27348-57.
33. Li A, Dubey S, Varney ML, Dave BJ, Singh RK,. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003; 170: 3369-76.
34. Shrikant P, Chung IY, Ballestas ME, Benveniste EN,. Regulation of intercellular adhesion molecule-1 gene expression by tumor necrosis factor-α, interleukin-1 β, and interferon-γ in astrocytes. J Neuroimmunol 1994; 51: 209-20.
35. Holmqvist K, Cross MJ, Rolny C, Hagerkvist R, Rahimi N, Matsumoto T, Claesson-Welsh L, Welsh M,. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem 2004; 279: 22267-75.
36. Takahashi T, Yamaguchi S, Chida K, Shibuya M,. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 2001; 20: 2768-78.
37. Hiratsuka S, Maru Y, Okada A, Seiki M, Noda T, Shibuya M,. Involvement of flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001; 61: 1207-13.
38. Zachary I, Gliki G,. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49: 568-81.
39. Rousseau S, Houle F, Kotanides H, Witte L, Waltenberger J, Landry J, Huot J,. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 2000; 275: 10661-72.
40. Thakker GD, Hajjar DP, Muller WA, Rosengart TK,. The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem 1999; 274: 10002-7.
41. Pedram A, Razandi M, Levin ER,. Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 1998; 273: 26722-8.
42. Kimura YN, Watari K, Fotovati A, Hosoi F, Yasumoto K, Izumi H, Kohno K, Umezawa K, Iguchi H, Shirouzu K, Takamori S, Kuwano M, et al. Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci 2007; 98: 2009-18.
43. Bar D, Apte RN, Voronov E, Dinarello CA, Cohen S,. A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J 2004; 18: 161-3.